share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4：持股變動聲明-股東 CR Group L.P.
美股sec公告 ·  05/08 05:03
牛牛AI助理已提取核心訊息
CR Group L.P. has reported a series of acquisitions of common stock in T2 Biosystems, Inc. [TTOO], according to a filing dated 05/03/2024. The transactions were made indirectly through various entities associated with CR Group L.P. A total of 648,139 shares were acquired by CRG Partners III L.P., 403,608 shares by CRG Partners III - Parallel Fund (A) L.P., 129,629 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,565,445 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 2,001,514 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions were classified under the transaction code 'A', indicating a grant, award, or other acquisition of securities. Following these transactions, the total number of shares held by CR Group L.P. in T2 Biosystems stands at 8,853,173. The nature of the indirect beneficial ownership is specified for each entity involved in the acquisitions.
CR Group L.P. has reported a series of acquisitions of common stock in T2 Biosystems, Inc. [TTOO], according to a filing dated 05/03/2024. The transactions were made indirectly through various entities associated with CR Group L.P. A total of 648,139 shares were acquired by CRG Partners III L.P., 403,608 shares by CRG Partners III - Parallel Fund (A) L.P., 129,629 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,565,445 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 2,001,514 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions were classified under the transaction code 'A', indicating a grant, award, or other acquisition of securities. Following these transactions, the total number of shares held by CR Group L.P. in T2 Biosystems stands at 8,853,173. The nature of the indirect beneficial ownership is specified for each entity involved in the acquisitions.
根據2024年3月5日的一份文件，CR集團有限責任公司報告了一系列收購T2 Biosystems, Inc. [TTOO] 普通股。這些交易是通過與CR集團有限責任公司相關的多個實體間接進行的。CRG Partners III L.P. 共收購了648,139股股票，CRG Partners III——平行基金（A）L.P. 收購了403,608股股票，CRG Partners III（開曼）Unlev I L.P. 收購了129,629股股票，CRG Partners III（開曼）AIV I L.P. 共收購了1,565,445股股票 L.P.，以及CRG Partners III——平行...展開全部
根據2024年3月5日的一份文件，CR集團有限責任公司報告了一系列收購T2 Biosystems, Inc. [TTOO] 普通股。這些交易是通過與CR集團有限責任公司相關的多個實體間接進行的。CRG Partners III L.P. 共收購了648,139股股票，CRG Partners III——平行基金（A）L.P. 收購了403,608股股票，CRG Partners III（開曼）Unlev I L.P. 收購了129,629股股票，CRG Partners III（開曼）AIV I L.P. 共收購了1,565,445股股票 L.P.，以及CRG Partners III——平行基金B（開曼）有限責任公司發行的2,001,514股股票。這些收購被歸類爲交易代碼 “A”，表示對證券的授予、獎勵或其他收購。這些交易完成後，CR集團有限責任公司在T2 Biosystems持有的股份總數爲8,853,173股。對於參與收購的每個實體，都規定了間接受益所有權的性質。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。